Genomics-Driven Immunoproteomics: An Integrative Platform to Uncover Important Biomarkers for Human Diseases

• DOI: 10.1007/978-1-4939-9597-4_21
• Publication Date: 2019-07-30T12:03:13Z
• Authors: Raghavendra Giri; Veneta Qendro; Pooja Rani; Carren Jepchumba; Grace Bugos; Volker Stadler; David K. Han
• Keywords: 0301 basic medicine; Proteomics; 0303 health sciences; 03 medical and health sciences; High-Throughput Nucleotide Sequencing; Humans; Biomarkers; Autoimmune Diseases; 3. Good health

Genomics-driven immunoproteomics (GDI) is a platform that helps identify antigenic protein targets of mutations and other deoxyribonucleic acid (DNA) variations that are commonly associated with pathological states. This platform utilizes data generated from deep sequencing of exomic DNA or ribonucleic acid (RNA) as input to synthesize mutant peptides into microarrays, which then can be used to detect antigenic proteins that invoke immune response in patients. The technology has been used to detect antigenic targets of multiple sclerosis, an autoimmune disease [1], and cancer to identify mutant proteins that invoke immune response in breast cancer patients [2]. This technology has many potential applications to select genomic changes that are specifically recognized by the immune system in a rapid and efficient manner.